3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Pancreatic Neoplasms
58
Carcinoma, Non-Small-Cell Lung
34
Urinary Bladder Neoplasms
29
Neoplasm Metastasis
20
Lung Neoplasms
19
Ovarian Neoplasms
18
Lymphoma, Large B-Cell, Diffuse
18
Cholangiocarcinoma
16
Biliary Tract Neoplasms
14
Triple Negative Breast Neoplasms
13
Neoplasms
13
Nasopharyngeal Carcinoma
13
Colorectal Neoplasms
12
Breast Neoplasms
12
Carcinoma, Transitional Cell
11
Non-Muscle Invasive Bladder Neoplasms
10
Recurrence
9
Fallopian Tube Neoplasms
9
Gallbladder Neoplasms
8
Sarcoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Bile Duct Neoplasms
6
Osteosarcoma
5
Lymphoma, Non-Hodgkin
5
Lymphoma
5
Endometrial Neoplasms
5
Uterine Cervical Neoplasms
4
Melanoma
4
Lymphoma, T-Cell, Peripheral
4
Hodgkin Disease
4
Interventions
liposomal doxorubicin
1
fludarabine
1
dostarlimab
1
Paclitaxel
1
Nivolumab
1
Ipilimumab
1
Gemcitabine
1
Doxorubicin
1
Dexamethasone
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma, Clear Cell
×
Gemcitabine
×
90 days
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled